Product Images Jasmiel

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Jasmiel NDC 53002-1783 by Rpk Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1 - drospirenone fig1

Figure 1 - drospirenone fig1

This text provides a figure showing the adjusted risk of developing VTE with Yasmin compared to other LNG-containing COCs. The risk ratios are shown on a logarithmic scale, where a ratio <1 represents a lower risk with Yasmin, and a ratio >1 indicates increased risk. The text also includes references to several studies that have evaluated the risk of VTE associated with Yasmin and other COCs. Adjustment factors are indicated by superscript letters.*

Figure 2 - drospirenone fig2

Figure 2 - drospirenone fig2

The text refers to a figure that shows the number of non-pregnant and non-COC users likely to develop a VIE (venous thromboembolism) based on a number of women with a blood clot out of 10,000 women years. The likelihood of developing VIE is also shown in postpartum ranges of up to 12 weeks. The data related to pregnancy is based on actual pregnancy duration in reference studies, with a model assumption of nine months leading to a rate of 7 to 27 per 10,000 women years.*

Figure3 - drospirenone fig3

Figure3 - drospirenone fig3

This text appears to be a list of different methods of birth control, including implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal ring with hormones, condoms, diaphragm, no sex during the most fertile days of the monthly cycle, spermicide, withdrawal. The text also provides statistics regarding pregnancy rates, with fewer than 1 pregnancy per 100 pregnancies per year, and 10-20 pregnancies per 100 women per year. For women who do not want to become pregnant, choosing one of the available birth control methods can be a practical solution.*

Figure4 - drospirenone fig4

Figure4 - drospirenone fig4

Figure5 - drospirenone fig5

Figure5 - drospirenone fig5

This is a table showing the number of women with a blood clot out of 10,000 women years (WY) for different categories: Non-Pregnant Non-COC user, COC-user, Pregnancy, and Postpartum (12 weeks only). The values for Non-COC user and COC-user are missing. The pregnancy data is shown based on actual duration of pregnancy in the reference studies, and based on a model assumption that pregnancy duration is nine months, the rate is between 7 to 27 per 10,000 WY.*

Chemical Str - drospirenone str

Chemical Str - drospirenone str

Drospirenone and ethinyl estradiol are two synthetic hormones commonly found in combination oral contraceptive pills. They work to prevent pregnancy by suppressing ovulation, thickening cervical mucus, and altering the lining of the uterus. This combination is also used to treat acne in women who experience hormonal breakouts.*

Label Image - lbl530021783

Label Image - lbl530021783

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.